ReviewJournal of child neurology2016
Medulloblastoma.
Review in Journal of child neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 150 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 5 syntheses or guidelines pooled it, 237 citations in OpenAlex.
- The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients.Cancer research · 2025Pooled it
- Risk Factors for Survival in Patients With Medulloblastoma: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Neuroimaging Biomarkers and Neurocognitive Outcomes in Pediatric Medulloblastoma Patients: a Systematic Review.Cerebellum (London, England) · 2021Pooled it
- What are the applications of single-cell RNA sequencing in cancer research: a systematic review.Journal of experimental & clinical cancer research : CR · 2021Pooled it
- Pooled it
- Establishing a Clinically Relevant Radiation Therapy Method for Preclinical Medulloblastoma Research.Advances in radiation oncology · 2026Article
- Medulloblastoma-associated mutations in the RNA helicase DDX3X/DED1 cause defects in the translational response to TORC1 inhibition.The Journal of biological chemistry · 2026Article
- A case-control study of MRI features in pediatric atypical teratoid rhabdoid tumor and medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- PCK2 as a potential therapeutic target for aggressive MYC-amplified non-WNT/non-SHH medulloblastoma based on tumor continuum.Acta neuropathologica communications · 2026Article
- The SHH/GLI target Netrin-1 supports self-renewal in medulloblastoma tumor cells.Cell communication and signaling : CCS · 2026Article
- AhR-Siglec-15 axis regulates lysosomal Ca2+ release for sonic hedgehog medulloblastoma growth via TRPML1.Protein & cell · 2026Article
- Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma: Characterization of In Vitro and In Vivo Pharmacokinetic Properties.Molecules (Basel, Switzerland) · 2026Article
- Ependymoma group-specific blood-brain barrier differences uncovered by a multi-omics approach.Scientific reports · 2026Article
- Significance of LEF1, ROR2, Cyclin D1, and DNA Methylation Profiling in the Molecular Classification and Prognosis Prediction of Pediatric Medulloblastoma.Balkan medical journal · 2026Article
- Medulloblastoma in Adolescents and Young Adults: Molecular Subgroups, Prognostic Biomarkers, and Age-Specific Therapeutic Challenges.Current issues in molecular biology · 2026Review
- TrkA activation sustains chemotherapy resistance in chemotolerant medulloblastoma cells.Acta neuropathologica communications · 2026Article
- Prognostic Factors of Dysphagia and Recovery Following Pediatric Acquired Brain Injury.Children (Basel, Switzerland) · 2026Article
- Precision medicine directed therapy enabling long-term survival in medulloblastoma: a case report.Frontiers in oncology · 2026Article
- In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients.Scientific reports · 2025Article
- The role of DNA methylation in directing treatment in medulloblastoma.Epigenomics · 2025Review
90 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrigendum.2016
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Medulloblastoma accounts for nearly 10% of all childhood brain tumors. These tumors occur exclusively in the posterior fossa and have the potential for leptomeningeal spread. Treatment includes a combination of surgery, radiation therapy (in patients >3 years old). Patients >3 years old are stratified based on the volume of postoperative residual tumor and the presence or absence of metastases into "standard risk" and "high risk" categories with long-term survival rates of approximately 85% and 70%, respectively. Outcomes are inferior in infants and children younger than 3 years with exception of those patients with the medulloblastoma with extensive nodularity histologic subtype. Treatment for medulloblastoma is associated with significant morbidity, especially in the youngest patients. Recent molecular subclassification of medulloblastoma has potential prognostic and therapeutic implications. Future incorporation of molecular subgroups into treatment protocols will hopefully improve both survival outcomes and posttreatment quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.